Venus launches new drug in anti-infective segment
Venus Remedies Ltd on Wednesday said it has launched Mucomelt-Forte, an anti-biotic in the domestic market, further enhancing its focus on the anti-infective segment.
By PTI |
MUMBAI: Venus Remedies Ltd on Wednesday said it has launched Mucomelt-Forte, an anti-biotic in the domestic market, further enhancing its focus on the anti-infective segment.
This launch would further expand the company's product basket for domestic operations, the pharmaceutical company informed the Bombay Stock Exchange.
The company's Biocard division launched the drug for the first time in the country. This combination was launched in the anti-biotic segment for the treatment of respiratory tract infections and Chronic Obstructive Pulmonary Disease (COPD), it added.
This new formulation would be helpful for Bronchitis patients and would also help in enhancing antibiotic penetration.
The formulation is proved to be a superior cure as compared to treatment with other antibiotics like Cefaclor and Cefuroxime.
Shares of the company were trading at Rs 385, up 1.09 per cent on the BSE.
This launch would further expand the company's product basket for domestic operations, the pharmaceutical company informed the Bombay Stock Exchange.
The company's Biocard division launched the drug for the first time in the country. This combination was launched in the anti-biotic segment for the treatment of respiratory tract infections and Chronic Obstructive Pulmonary Disease (COPD), it added.
This new formulation would be helpful for Bronchitis patients and would also help in enhancing antibiotic penetration.
The formulation is proved to be a superior cure as compared to treatment with other antibiotics like Cefaclor and Cefuroxime.
Shares of the company were trading at Rs 385, up 1.09 per cent on the BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
